Secondary Navigation Menu

Audience Switcher Modal

Country and Audience Choose Modal

Some of the compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities.

Scientific Congress Publications

Supported by Bayer Pharmaceuticals

EASD 2026

FINERENONE

Impact of finerenone on kidney-cardio outcomes by baseline HbA1c levels in a broad chronic kidney disease population: a pooled analysis (INFINITY)
Date:
September 28, 2026
Session:
LBA SO 08 Novel insights into diabetes and obesity
Type:
ePoster
Presenting Author:
David Cherney
Download the poster More info
Effect of BMI on kidney-cardio outcomes with finerenone in a broad CKD population (INFINITY)
Date/Time:
October 2, 2026 | 10:00 – 10:15 CEST
Session:
LBA OP 06 Predictors of outcomes and subtypes
Type:
Oral Presentation
Presenting Author:
Peter Rossing
Download the presentation More info
Efficacy and safety of finerenone by age in patients with chronic kidney disease and type 1 diabetes
Date/Time:
October 1, 2026 | 15:30 – 15:45 CEST
Session: ​
OP 32 Diabetic kidney disease: from mechanisms to novel horizons
Type: ​
Oral Presentation
Presenting Author:
Sylvia E. Rosas
Download the presentation More info
Effectiveness of finerenone in reducing UACR in patients with chronic kidney disease and type 2 diabetes in the United States
Date:
September 28, 2026
Session: ​
SO 106: Putting the brakes on DKD: therapeutic strategies
Type: ​
Short Oral
Presenting Author:
Nikolaus G. Oberprieler
Download the presentation More info
Back to Cardiovascular, Renal, & Pulmonary

© 2026 Bayer. All rights reserved.
Bayer and the Bayer Cross are registered trademarks of Bayer.

Copies of the Bayer Pharmaceuticals supported presentations obtained from this platform are for personal use only and may not be reproduced or distributed without permission from the authors.

Some of the compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities, and the presentations are shared in the interest of scientific exchange.

For any questions, please contact Medical Information at https://www.medicalinformation.bayer.com/

PP-GEN-ALL-0014-1